Roche Signs Up To Be Regeneron’s Global Partner For COVID Antibody
Deal Will Boost Manufacturing Of REGN-COV2
After failures in trials of repurposed drugs, the rivals will collaborate on Regeneron’s antibody cocktail which could prevent coronavirus infection.
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
CEO Len Schleifer said he does not know the timeline for when the US FDA could authorize REGN-COV2 but expects to hear from the agency soon.
A study presented at a recent MIT-sponsored conference used network medicine to uncover dozens of potential opportunities for existing drugs to be repurposed for COVID-19.